As cannabis legalization has impacted the variety of cannabis products available, there appears to be growing numbers of patients with multiple sclerosis (PwMS) using cannabis, with this recent study's cannabis users (CUs) reporting use of highly efficacious products with minimal side-effects. Researchers evaluated cannabis use among PwMS at a large academic MS clinic, specifically: 1) prevalence; 2) products used; 3) symptom treatment; and 4) patient characteristics. PwMS completed questions assessing personal opinions about cannabis use, characteristics of cannabis use, MS history, diagnosis, sociodemographic details, as well as the self-reported disability-Patient Determined Disease Steps (PDDS), overall quality of life-the Patient Reported Outcome Measure Information System (PROMIS-10), and cognition-the Neuro-QoL ACGC v1.0 measures. Researchers found:

• 38% (n=96) of PwMS were current CUs.
• Although there were no sociodemographic or clinical differences between CUs and non-cannabis users (NUs), CUs had significantly higher median disability compared to NUs (PDDS = 2 vs 1).
• Among CUs, 57% categorized their use as strictly medicinal.
• CUs reported using cannabis most often for pain and insomnia/poor sleep and experienced >60% benefit/relief from cannabis use.